Peak Retirement Planning Inc. Has $2.59 Million Position in Abbott Laboratories $ABT

Peak Retirement Planning Inc. increased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 46.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 19,369 shares of the healthcare product maker’s stock after acquiring an additional 6,160 shares during the period. Abbott Laboratories comprises about 0.7% of Peak Retirement Planning Inc.’s investment portfolio, making the stock its 26th biggest position. Peak Retirement Planning Inc.’s holdings in Abbott Laboratories were worth $2,594,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in ABT. IMG Wealth Management Inc. raised its stake in Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after acquiring an additional 167 shares in the last quarter. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories during the 3rd quarter worth about $29,000. Guerra Advisors Inc bought a new position in Abbott Laboratories during the 3rd quarter valued at about $31,000. Anfield Capital Management LLC boosted its position in Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after buying an additional 104 shares in the last quarter. Finally, Delos Wealth Advisors LLC bought a new stake in Abbott Laboratories during the second quarter worth about $32,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 0.2%

Abbott Laboratories stock opened at $109.51 on Tuesday. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The firm has a market capitalization of $190.43 billion, a price-to-earnings ratio of 29.44, a PEG ratio of 1.74 and a beta of 0.75. The company’s 50 day simple moving average is $122.41 and its 200 day simple moving average is $127.35.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The company had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same period last year, the firm posted $1.34 earnings per share. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Analyst Upgrades and Downgrades

ABT has been the topic of several recent analyst reports. Argus reduced their target price on Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Royal Bank Of Canada decreased their target price on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Citigroup cut their price target on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Evercore ISI reduced their price target on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Finally, William Blair raised Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, November 20th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $137.05.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s CEO personally invested roughly $2M while the stock has been under pressure — a management buy that signals confidence to shareholders and can help stabilize sentiment. Article Title
• Positive Sentiment: Freedom Capital upgraded ABT to a Buy (recently lowering its PT to $120), which gives the stock a retail/institutional buying narrative despite the lower target. Article Title
• Positive Sentiment: Long‑term bull case pieces note Abbott’s Dividend Aristocrat status, multi‑year revenue growth and strong balance sheet, reinforcing a buy-and-hold thesis for income/quality investors. Article Title
• Positive Sentiment: Opinion/bull-case coverage outlines structural upside from diagnostics and recurring revenue streams, offering a narrative that could attract growth‑oriented buyers. Article Title
• Neutral Sentiment: Abbott’s deal with Exact Sciences is reshaping its diagnostics footprint (strategic upside), but its nutrition business is undergoing a reset — a mixed development that likely means longer lead times before clear earnings upside. Article Title
• Neutral Sentiment: Barclays trimmed its price target from $169 to $142 but kept an Overweight rating, signaling conviction in Abbott’s story despite near-term headwinds. Article Title
• Neutral Sentiment: Valuation comparisons (e.g., Zacks piece on NVST vs ABT) highlight Abbott as a relatively lower-volatility, dividend-oriented option — useful context but not an immediate catalyst. Article Title
• Negative Sentiment: Daiwa cut its price target to $113 — a downgrade that adds selling pressure from analysts and may weigh on near‑term sentiment. Article Title
• Negative Sentiment: Leerink lowered its target to $119, another analyst haircut that contributes to a chorus of reduced near‑term expectations. Article Title

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.